Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X
- PMID: 24256699
- DOI: 10.1097/MCA.0000000000000054
Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X
Abstract
Objectives: Statins and calcium channel blockers have been proven beneficial toward improvement of endothelial function. The aim of this study was to compare the effect of combination therapy of statin and calcium channel blocker with solo treatment in patients with cardiac syndrome X.
Methods and results: Sixty-eight patients with cardiac syndrome X were divided randomly into three groups: fluvastatin (40 mg/day, n=23), diltiazem (90 mg/day, n=22), and combination of fluvastatin (40 mg/day) and diltiazem (90 mg/day, n=23). At the end of 90 days, the coronary flow reserve was improved in the three groups (fluvastatin-treated group: 23.2%; diltiazem-treated group: 12.4%; fluvastatin+diltiazem-treated group: 29.1%, all P<0.05). The time to 1 mm ST segment depression increased significantly in the fluvastatin-treated group (from 241±97 to 410±140 s, P<0.05), the diltiazem-treated group (from 258±91 to 392±124 s, P<0.05), and the fluvastatin+diltiazem-treated group (from 250±104 to 446±164 s, P<0.05). The improvement in coronary flow reserve and prolonged time to 1 mm ST segment depression in the combination treatment group were more remarkable than in those who received monotherapy. Combination therapy also induced a significant increase (35.6%, P<0.05) in nitric oxide and an apparent reduction (48.7%, P<0.05) in endothelin-1.
Conclusion: Combination treatment with fluvastatin and diltiazem is more effective on endothelial function and exercise tolerance than solo treatment in patients with cardiac syndrome X. The benefits of these drugs may be related to the elevation of nitric oxide and reduction of endothelin-1.
Similar articles
-
Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers.J Am Coll Cardiol. 2008 May 6;51(18):1742-8. doi: 10.1016/j.jacc.2007.12.049. J Am Coll Cardiol. 2008. PMID: 18452779 Clinical Trial.
-
Effect of diltiazem on coronary flow reserve in patients with microvascular angina.Int J Cardiol. 1995 Nov 24;52(2):135-43. doi: 10.1016/0167-5273(95)02458-9. Int J Cardiol. 1995. PMID: 8749873 Clinical Trial.
-
Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV).Ann Surg. 2009 Jun;249(6):921-6. doi: 10.1097/SLA.0b013e3181a77d00. Ann Surg. 2009. PMID: 19474688 Clinical Trial.
-
Microvascular angina: prevalence, pathophysiology and therapy.J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e36-e39. doi: 10.2459/JCM.0000000000000638. J Cardiovasc Med (Hagerstown). 2018. PMID: 29538142 Review. No abstract available.
-
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence.Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec;5(6):489-501. doi: 10.2174/156800605774962112. Curr Drug Targets Cardiovasc Haematol Disord. 2005. PMID: 16503869 Review.
Cited by
-
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned.Curr Atheroscler Rep. 2022 Sep;24(9):681-687. doi: 10.1007/s11883-022-01044-4. Epub 2022 Jul 4. Curr Atheroscler Rep. 2022. PMID: 35781776 Free PMC article. Review.
-
Doppler Echocardiography Assessment of Coronary Microvascular Function in Patients With Angina and No Obstructive Coronary Artery Disease.Front Cardiovasc Med. 2021 Oct 29;8:723542. doi: 10.3389/fcvm.2021.723542. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34778394 Free PMC article. Review.
-
Coronary Microvascular Dysfunction and Vasospastic Angina-Pathophysiology, Diagnosis and Management Strategies.J Clin Med. 2025 Feb 10;14(4):1128. doi: 10.3390/jcm14041128. J Clin Med. 2025. PMID: 40004660 Free PMC article. Review.
-
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.Eur Heart J. 2020 Oct 1;41(37):3504-3520. doi: 10.1093/eurheartj/ehaa503. Eur Heart J. 2020. PMID: 32626906 Free PMC article.
-
Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries: Current Gaps and Future Directions.Drugs. 2022 Feb;82(3):241-250. doi: 10.1007/s40265-021-01667-y. Epub 2022 Jan 29. Drugs. 2022. PMID: 35092594 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
